Everything below concerns reversed-phase HPLC. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-12-27. Numbers and descriptions here follow the published literature rather than marketing material.
Clinical studies of semaglutide generally measure glycated hemoglobin, fasting plasma glucose, body weight, and composite cardiovascular endpoints. The SUSTAIN program enrolled adults with type 2 diabetes, while the STEP program focused on obesity without diabetes. Administration follows a stepwise escalation schedule designed to limit gastrointestinal effects during the first weeks. Reported outcomes include mean percentage weight change, the proportion of participants reaching defined weight-loss thresholds, and rates of nausea, vomiting, and diarrhea. Long-term data on durability after treatment stops are still limited and remain a topic of ongoing research.
Semaglutide is a synthetic peptide analog of human glucagon-like peptide-1, developed by Novo Nordisk and first approved in 2017 for type 2 diabetes. It belongs to the incretin mimetic class, a group of agents that reproduce the glucose-dependent actions of endogenous GLP-1. The molecule was engineered to resist degradation by dipeptidyl peptidase-4 and to bind serum albumin, extending its half-life from minutes to roughly one week. Approval for chronic weight management followed in 2021, based on large cardiovascular and obesity outcome trials.
Receptor activation occurs at GLP-1 receptors distributed across pancreatic islets, the hypothalamus, and the gastrointestinal tract. Binding triggers G protein signaling that raises cyclic AMP and enhances glucose-dependent insulin release. Because the effect depends on prevailing glucose levels, insulin secretion does not rise when blood sugar is already low. Signaling in the brain and gut also influences appetite and gastric emptying, which is why the compound appears in both metabolic and weight-related research literature.
Development began in the early 2010s with the goal of extending GLP-1 activity beyond the brief window achieved by native peptide infusion. The earliest approved formulation was a subcutaneous injection given once weekly. A later oral tablet pairs the peptide with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, usually shortened to SNAC. That carrier lowers local pH and helps the peptide cross gastric tissue. Both routes deliver the same active molecule.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C187H291N45O59 | Peptide backbone with a C18 fatty diacid side chain |
| Molecular weight | Approximately 4113 Da | Consistent with a 31-residue peptide plus linker |
| Appearance | White to off-white powder | Lyophilized solid; hygroscopic if left open |
| Solubility class | Sparingly soluble to soluble in water | Varies with pH and ionic strength |
| Typical analytical method | Reversed-phase HPLC with UV detection | Often paired with mass spectrometry for identity |
Material described as research-grade is not necessarily manufactured to pharmaceutical standards, and purity figures depend on the method used to obtain them. A certificate of analysis states the measured purity, the analytical technique, and the batch identifier, but the underlying data are not always included. Independent testing by a second laboratory is a common way to confirm identity and purity. Uncertainties remain about how storage history affects long-term stability, and about how well results from one laboratory transfer to another. Documentation of handling conditions supports comparison between batches.
Peptides are sensitive to temperature, light, oxygen, and repeated freeze-thaw cycles. Semaglutide in dry form is generally held at refrigerated temperatures, while reconstituted solutions require a defined short-term storage window. Vials should be kept in secondary packaging to limit photodegradation, and exposure to alkaline conditions is avoided because it accelerates chemical degradation. Adsorption to glass and some plastics can reduce the measured concentration of dilute solutions, so low-binding polypropylene containers are preferred for analytical work. Each transfer step introduces a small risk of contamination, and closed handling practices reduce that risk.
Quantification and purity assessment rely on separation methods coupled to optical or mass detection. Reversed-phase high-performance liquid chromatography resolves the intact peptide from related impurities and is the standard assay technique. Size-exclusion chromatography measures aggregates, while ion-exchange chromatography separates charge variants produced by deamidation. Mass spectrometry confirms identity and detects mass shifts of a few daltons. In biological matrices, liquid chromatography with tandem mass spectrometry is often used because immunoassays can cross-react with endogenous GLP-1 or with circulating fragments.
As a peptide, semaglutide is sensitive to conditions that break amide bonds or modify side chains. Deamidation of asparagine and glutamine residues, oxidation of methionine and tryptophan, and non-covalent aggregation are the main degradation routes described in published stability work. Rate depends strongly on pH, buffer species, ionic strength, temperature and exposure to light. Formulators therefore choose a defined solution pH and often add excipients such as phosphate buffer, propylene glycol and phenol, each of which plays a separate role in pH control, tonicity or preservation.
Quality control relies on pharmacopoeial monographs where they exist, combined with in-house specifications for identity, purity, water content, and counter-ion composition. Reference standards allow calibration across laboratories, although certified materials for every analogue are not universally obtainable. Batch records, chromatograms, and mass spectra form the documentation trail. Regulatory classification varies by jurisdiction and intended use, and research-grade material differs from pharmaceutical-grade material in testing scope. Analytical uncertainty is often expressed as relative standard deviation across replicate injections.
Lyophilised semaglutide is generally held at -20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept at 2-8 °C and used within a defined window because degradation accumulates over time. Repeated freeze-thaw cycles are discouraged, since each cycle can promote aggregation and reduce monomeric content. Room-temperature stability of the solid has been examined in some studies but remains incompletely characterised for long durations, so cold storage is the conservative default for research material.
Degradation proceeds along several parallel routes. Deamidation of asparagine and glutamine residues generates charged variants that shift retention time in chromatographic analysis. Oxidation targets methionine and can be accelerated by trace metals or dissolved oxygen. Non-covalent aggregation produces dimers, oligomers, and larger species that are difficult to reverse. Isomerisation at aspartate residues is slower but measurable under thermal stress. The distribution among these pathways depends on pH, buffer composition, ionic strength, and the presence of excipients such as sugars or surfactants.
关于降解产物的免疫原性风险，文献中仍有讨论空间。体外聚集水平与临床免疫反应之间的定量关系尚未确立。多数公开研究只报告理化指标，缺少长期随访的对应数据。这一问题在生物类似物比对中尤其受到关注。
市售注射用制剂通常要求在二至八摄氏度冷藏保存，并避免光照与冻结。部分多剂量笔在首次使用后允许在不超过三十摄氏度的环境中存放有限周数，具体期限由辅料与防腐剂体系决定。反复冻融会促进肽链聚集并改变可见颗粒计数，因此应予避免。冻干粉末在干燥、避光、低温条件下更为稳定。溶液配制后宜使用低吸附容器，以减少肽类在塑料或玻璃表面的损失。
纯度评价多采用反相高效液相色谱，流动相常加入三氟乙酸或甲酸作为离子对改性剂，检测波长设在二百一十四纳米或二百二十纳米。分子量确认依靠电喷雾电离质谱或基质辅助激光解吸电离质谱，实测值应与理论值在数 ppm 内吻合。肽图分析通过酶切后液相色谱串联质谱完成，用于核查序列与修饰位点。体积排阻色谱用于定量共价与非共价聚集体。生物基质浓度测定则采用免疫分析或液相色谱串联质谱。
== See also == Chemical pneumonitis Composition of heated tobacco product emissions Adverse effects of electronic cigarettes List of additives in cigarettes List of cigarette smoke carcinogens Safety of electronic cigarettes Vaping-associated pulmonary injury
=== Muscle biopsy === If DNA testing fails to find the mutation, a muscle biopsy test may be performed. A small sample of muscle tissue is extracted using a biopsy needle. The key tests performed on the biopsy sample for Duchenne muscular dystrophy are immunohistochemistry, immunocytochemistry, and immunoblotting for dystrophin, and should be interpreted by an experienced neuromuscular pathologist. These tests provide information on the presence or absence of the protein. Absence of the protein is a positive test for Duchenne muscular dystrophy. Where dystrophin is present, the tests indicate the amount and molecular size of dystrophin, helping to distinguish Duchenne muscular dystrophy from milder dystrophinopathy phenotypes. Over the past several years, DNA tests have been developed that detect more of the many mutations that cause the condition, and muscle biopsy is not required as often to confirm the presence of Duchenne muscular dystrophy.
1993/453) National Rivers Authority (Anglian Region) (Reconstitution of the North Level Internal Drainage Board) Order 1992 S.I. 1993/454) Environmentally Sensitive Areas (Breckland) Designation Order 1993 (S.I. 1993/455) Environmentally Sensitive Areas (Clun) Designation Order 1993 (S.I. 1993/456) Environmentally Sensitive Areas (North Peak) Designation Order 1993 (S.I. 1993/457) Environmentally Sensitive Areas (Suffolk River Valleys) Designation Order 1993 (S.I. 1993/458) Environmentally Sensitive Areas (Test Valley) Designation Order 1993 (S.I. 1993/459) Environmentally Sensitive Areas (Pennine Dales) Designation (Amendment) Order 1993 (S.I. 1993/460) National Assistance (Sums for Personal Requirements) Regulations 1993 (S.I. 1993/462) Education (Further Education Corporations) (Designated Staff) Order 1993 (S.I. 1993/465) Bradford, Kirklees and Leeds (City and Metropolitan Borough Boundaries) Order 1993 (S.I. 1993/473) Warwickshire and West Midlands (County and District Boundaries) Order 1993 (S.I. 1993/474) Merchant Shipping (Light Dues) (Amendment) Regulations 1993 (S.I. 1993/475) Wireless Telegraphy (Television Licence Fees) (Amendment) Regulations 1993 (S.I. 1993/476) Residential Accommodation (Relevant Premises, Ordinary Residence and Exemptions) Regulations 1993 (S.I. 1993/477) Social Security (Claims and Payments) Amendment Regulations 1993 (S.I. 1993/478) Social Fund Maternity and Funeral Expenses (General) Amendment Regulations 1993 (S.I. 1993/479) Personal Injuries (Civilians) Amendment Scheme 1993 (S.I.
=== 68Ga radiolabeling === 68Ga-Trivehexin is a radioactive drug. The radioactive atom, gallium-68 (68Ga), decays with a half-life of approximately 68 min to the stable isotope zinc-68 (68Zn), to 89% by β+ decay whereby a positron with a maximum kinetic energy of 1.9 MeV is emitted (the remaining 11% are EC decays). Due to the short half-life, 68Ga-Trivehexin can not be manufactured long before use but the 68Ga has to be introduced into the molecule shortly before application. This process is referred to as radiolabeling, and is done by complexation of the trivalent cation 68GaIII by the TRAP chelator in Trivehexin. 68GaIII is usually obtained from a dedicated mobile radionuclide source, a Gallium-68 generator, in form of a solution in dilute (0.04–0.1 M) hydrochloric acid (frequently and imprecisely referred to as "68Ga chloride solution in HCl" despite it contains no species with a Ga–Cl bond but [68Ga(H2O)6]3+ complex hydrate cations). For radiolabeling, the pH of the 68Ga containing generator eluate has to be raised from its initial value (depending on HCl concentration, pH 1–1.5) to pH 2–3.5 using suitable buffers, such as sodium acetate. Then, Trivehexin (5–10 nmol) is added to the buffered 68Ga-containing solution, and the mixture is briefly heated to 50–100 °C (usually 2–3 min) to finalize the complexation reaction.
Sources: en.wikipedia.org
== Invertebrates == In some invertebrates, such as Porifera, Cnidaria, Ctenophora, and some triploblasts (namely the acoelomates), the term "mesenchyme" refers to a more-or-less solid but loosely organized tissue that consists of a gel matrix (the mesoglea) with various cellular and fibrous inclusions, located between the epidermis and the gastrodermis (non-triploblast animals usually are considered to lack "connective" tissue). In some cases, the mesoglea is noncellular.
Research links regular MDMA use to reduced grey matter volume, particularly in the hippocampus. Structural MRI scans show significant volume reductions in the hippocampus, specifically subregions such as CA1, which directly control memory formation.
== Awards, distinctions and memberships == 2000: Ernst Bloch Promotional Award for his book Gott ist schön. Das ästhetische Erleben des Koran [Godi s Beautiful. The Aesthetic Experience of the Koran] (1999) 2003: Annual Prize of the Helga-und-Edzard-Reuter-Foundation 2004: Schwarzkopf-Europe-Prize of the Foundation Schwarzkopf-Stiftung Junges Europa 2007: Member of the Deutsche Akademie für Sprache und Dichtung 2008: Fellowship of the Villa Massimo in Rom 2009: Hessian Cultural Prize 2011: Nomination of the novel Dein Name for the German Book Prize 2011: Buber-Rosenzweig-Medal 2011: Hannah Arendt Prize; Award Presentation Speech: Marie Luise Knott 2012: Kleist Prize for the novel Dein Name (2011) 2012: Honorary Prize of the City of Cologne Culture Prize Kölner Kulturpreises 2012: Cicero Prize for public speaking 2014: Gerty Spies Literature Prize 2014: Prize of the Association of German Institutions of Dialogue des BDDI 2014: Joseph Breitbach Prize 2015: North Rhine-Westphalian Academy of Sciences, Humanities and the Arts, Member 2015: Peace Prize of the German Publishers' Association 2015: Jan Michalski Prize for Literature finalist for Zwischen Koran und Kafka: West-östliche Erkundungen 2016: Marion Dönhoff Prize for International Understanding and Reconciliation 2017: Hermann Sinsheimer Prize of the City of Freinsheim 2017: ECF Princess Margriet Award for Culture of the European Cultural Foundation 2017: Civic Engagement Award of the German Newspaper Publishers, Award Presentation Speech: Wolf Lepenies 2017: State Prize of the Federal State North Rhine-Westphalia, Award Presentation Speech: Wolfgang Schäuble 2018: Samuel Bogumil Linde Prize; Award Presentation Speech: Joachim Gauck 2020: Friedrich-Hölderlin-Preis 2021: Appointed Honorary Member of the Board of Trustees of the WDR Symphony Orchestra Cologne 2021: Austrian Book Publishers Award for Tolerance in Thought and Action 2022: Honorary Degree of the Philosophy Department of the University of Siegen 2023: Member of the authors association PEN Berlin 2023: Winfried Prize of the City of Fulda 2023: Hans Ehrenberg Prize 2024: Thomas Mann Prize 2026: Bundesverdienstkreuz 1. Klasse
on the toxicity findings of publicly-funded academics, whose methods are very heterogeneous, but who test, and often find, toxicity at much lower doses that industry's TG studies); or, a nation may interpret the accepted study's results according to its own criteria. According to OECD Council Decision C(97)186/Final, chemical testing data generated in any OECD member country following OECD Test Guidelines and GLP principles is recognized by other OECD member countries, such as Australia, Canada, Korea, and the USA. This recognition also extends to some non-OECD countries that fully adhere to the mutual acceptance of data (MAD) under OECD Council Decision C(97)114/Final, including Brazil, India, Malaysia, Singapore, and South Africa, as well as Argentina for industrial chemicals, pesticides, and biocides only. In June 2004, the US FDA published a comparison chart of FDA and EPA Good Laboratory Practice (GLP) regulations alongside OECD Principles for GLP, aiding in understanding the key differences and similarities in GLP standards across these regulatory bodies. Note, unlike many countries, the US EPA names its mandated use of the OECD TG, ‘the EPA Test Methods’.
GLP-1 possesses several physiological properties making it (and its functional analogs) a subject of intensive investigation as a potential treatment of diabetes mellitus, as these actions induce long-term improvements along with the immediate effects. Although reduced GLP-1 secretion has previously been associated with attenuated incretin effect in patients with type 2 diabetes, further research indicates that GLP-1 secretion in patients with type 2 diabetes does not differ from healthy subjects. The most noteworthy effect of GLP-1 is its ability to promote insulin secretion in a glucose-dependent manner. As GLP-1 binds to GLP-1 receptors expressed on pancreatic β cells, the receptors couple to G-protein subunits and activate adenylate cyclase, which increases the production of cAMP from ATP. Subsequently, activation of secondary pathways, including protein kinase A (PKA) and Epac2, alters cell ion channel activity, causing elevated levels of cytosolic Ca2+ that enhance exocytosis of insulin-containing granules. During the process, influx of glucose ensures sufficient ATP to sustain the stimulatory effect. Additionally, GLP-1 ensures the β cell insulin stores are replenished to prevent exhaustion during secretion by promoting insulin gene transcription, mRNA stability and biosynthesis. GLP-1 also increases β cell mass by promoting proliferation and neogenesis while inhibiting apoptosis. As both type 1 and 2 diabetes are associated with reduction of functional β cells, this effect is desirable in diabetes treatment.
Sources: en.wikipedia.org
It is given either as a once-weekly subcutaneous injection or as an oral tablet taken once daily. The two forms use different absorption strategies, so they are not interchangeable on a milligram-for-milligram basis.
Structural modifications, including a fatty acid side chain and non-natural amino acid substitutions, slow enzymatic breakdown and promote albumin binding. These changes support once-weekly dosing rather than twice-daily administration.
The pathways involving insulin, glucagon, gastric emptying, and appetite signaling are well described. How much each pathway contributes to weight reduction in a given person is not fully established.
Native GLP-1 is degraded within minutes by circulating enzymes. The synthetic version carries substitutions at positions that block enzymatic cleavage, plus a fatty acid side chain that promotes albumin binding. These two changes together extend circulation time from minutes to roughly a week.